Compare RBA & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBA | RPRX |
|---|---|---|
| Founded | 1958 | 1996 |
| Country | United States | United States |
| Employees | 7900 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.8B | 19.4B |
| IPO Year | N/A | 2020 |
| Metric | RBA | RPRX |
|---|---|---|
| Price | $99.95 | $47.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $128.75 | $47.75 |
| AVG Volume (30 Days) | 1.7M | ★ 3.4M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | 1.23% | ★ 2.03% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.78 |
| Revenue | N/A | ★ $2,378,193,000.00 |
| Revenue This Year | $4.52 | $39.10 |
| Revenue Next Year | $3.94 | $5.02 |
| P/E Ratio | $52.68 | ★ $25.87 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $87.87 | $29.66 |
| 52 Week High | $119.58 | $46.37 |
| Indicator | RBA | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.57 | 80.55 |
| Support Level | $97.48 | $35.32 |
| Resistance Level | $106.54 | N/A |
| Average True Range (ATR) | 4.74 | 1.01 |
| MACD | -0.98 | 0.04 |
| Stochastic Oscillator | 16.15 | 98.79 |
RB Global has evolved into a leading global marketplace that connects buyers and sellers of commercial assets and vehicles. It is the result of the 2023 combination of Ritchie Bros. and IAA. Ritchie Bros.' roots were as an auctioneer facilitating transactions of commercial, construction, and transportation equipment (excavators, bulldozers, forklifts, and commercial trucks and trailers). However, it has evolved into an omnichannel marketplace. IAA has similar roots, though primarily focused on the salvage auction segment for consumer automobiles. The group provides ancillary services including title processing, transportation/towing, financing, data and appraisal, and so on. Its activities are international, though skewing approximately two-thirds to North America.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.